Christine Fox sold $327k of TEVA
EVP, Head of U.S. Commercial at TEVA PHARMACEUTICAL INDUSTRIES LTD. 19,388 shares at an average of $16.87, traded Nov 20, 2024, filed Nov 21, 2024.
Score components
- +15RoleOfficer
- +15Trade size$327k at market
- +10Share of holdings soldSold 31% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +29.3%, 3m -0.5%, 6m -0.8%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-24-129709, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 20, 2024 | MOption exercise Ordinary Shares10b5-1 | +63,492 | - | - | 63,492 | Nov 21, 2024 |
| Nov 20, 2024 | SOpen-market sale Ordinary Shares10b5-1 | -19,388 | $16.87 | $327k | 44,104 | Nov 21, 2024 |
| Nov 20, 2024 | MOption exercise Restricted Share Unitsderivative10b5-1 | -63,492 | $0.00 | $0 | 190,476 | Nov 21, 2024 |
Related signals
Other insiders at TEVA PHARMACEUTICAL INDUSTRIES LTD and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 68Notable | TEVA PHARMACEUTICAL INDUSTRIES LTD | Roberto Mignone director | $14M 367,600 shares | -100% | |
| 32Weak | TEVA PHARMACEUTICAL INDUSTRIES LTD | Brian Savage Interim Chief Legal Officer | $285k 7,342 shares | -46% | |
| 60Notable | TEVA PHARMACEUTICAL INDUSTRIES LTD | Mark Sabag See "Remarks" | $1.9M 62,102 shares | -22% | |
| 19Weak | TEVA PHARMACEUTICAL INDUSTRIES LTD | Richard Daniell EVP, Europe Commercial | $548k 17,295 shares | -17% | |
| 8Weak | TEVA PHARMACEUTICAL INDUSTRIES LTD | Christine Fox EVP, U.S. Commercial | $251k 7,924 shares | -9% | |
| 25Weak | TEVA PHARMACEUTICAL INDUSTRIES LTD | Richard D Francis President and CEO | $634k 20,025 shares | -2% | |
| 9Weak | TEVA PHARMACEUTICAL INDUSTRIES LTD | Eric A Hughes See "Remarks" | $302k 9,533 shares | -8% | |
| 32Weak | TEVA PHARMACEUTICAL INDUSTRIES LTD | Placid Jover See "Remarks" | $448k 14,150 shares | -68% | |
| 21Weak | TEVA PHARMACEUTICAL INDUSTRIES LTD | Brian Savage Interim Chief Legal Officer | $36k 1,127 shares | -9% | |
| 34Weak | TEVA PHARMACEUTICAL INDUSTRIES LTD | Matthew Shields EVP, Global Operations | $548k 17,295 shares | -63% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.